Deep Remission, Mucosal Healing, and Top-Down Treatment Strategies in Ulcerative Colitis: An Infographic JourneyPremiere Date: Monday, July 31, 2017
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, July 31, 2018
Note: Credit Is No Longer Available
|Maria T. Abreu, MD
Director, Crohn's & Colitis Center
Martin Kalser Chair in Gastroenterology
Professor of Medicine
Professor of Microbiology and Immunology
University of Miami Miller School of Medicine
Ulcerative colitis (UC) is an inflammatory bowel disease with a progressive course characterized by exacerbations and remissions. Traditionally, the goals of therapy for UC have entailed resolution of clinical symptoms such as rectal bleeding, bloody diarrhea, abdominal cramps, pain, and fatigue. However, treatment goals for UC have evolved to a treat-to-target strategy with targets such as mucosal/endoscopic healing, histologic healing, or deep remission (i.e., clinical, biochemical, and endoscopic remission) with the objective of preventing structural damage and disability. Conventional therapies have not been uniformly effective in achieving these aims, necessitating augmentation with steroids and carrying adverse risk often requiring discontinuation.
There has been an exponential growth in the pursuits of better targeted therapy to optimize IBD clinical outcomes. IBD therapies that explore new targets and inflammatory pathways are emerging to address the current treatment gaps observed with conventional and biologic therapies.
This CME Outfitters interactive infographic explains the importance of initiating early targeted biologic therapy and provides evidence-based strategies to take action to achieve sustained remission and long-term clinical outcomes.
At the end of this CE activity, participants should be able to:
- Apply an understanding of the mechanism of action of different biologic therapies to individualized treatment decisions for patients with ulcerative colitis (UC).
- Examine the role of initiating early, targeted biologic therapy in achieving sustained remission and mucosal healing.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Physicians, physician assistants, nurse practitioners, pharmacists, and other healthcare providers interested in treating patients with ulcerative colitis (UC).
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hour (0.05 CEUs) Universal Activity Number:0376-0000-17-034-H01-P
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Abreu reports she serves on the speaker's bureau for AbbVie Inc.; and Imedex. She is a consultant for Eli Lilly and Company; Focus Medical Communications; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Prometheus Laboratories Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Theravance Biopharma US, Inc.; and UCB, Inc. She serves on the scientific advisory board for AbbVie Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Roche Pharmaceuticals; and Shire.
Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.
Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).